Docoh
Loading...

Emerald Health Pharmaceuticals

Filed: 30 Apr 21, 4:04pm
schemaVersion:

1-K: Filer Information

Issuer CIK
0001700800
Issuer CCC
XXXXXXXX
Is filer a shell company? Radio button not checked Yes Radio button checked No
Is the electronic copy of an official filing submitted in paper format? Checkbox not checked
File Number
Is this filing by a successor company pursuant to Rule 257(b)(5) resulting from a merger or other business combination? Radio button not checked Yes Radio button checked No
Successor File Number

Submission Contact Information

Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
Would you like a Return Copy? Checkbox not checked
Period
12-31-2020
Name
Phone
E-Mail Address
Notify via Filing Website only? Checkbox not checked

1-K: Tab 1 Notification

This Form 1-K is to provide an Radio button checked Annual Report Radio button not checked Special Financial Report for the fiscal year
Fiscal Year End

12-31-2020

Exact name of issuer as specified in the issuer's charter

Emerald Health Pharmaceuticals Inc.

CIK

0001700800

Jurisdiction of Incorporation / Organization

DELAWARE

I.R.S. Employer Identification Number

82-0669961

Address of Principal Executive Offices

Address 1

5910 Pacific Center Blvd, Suite 320

Address 2

City

San Diego

State/Country

CALIFORNIA

Mailing Zip/ Postal Code

92121

Phone

858-352-0622

Title of each class of securities issued pursuant to Regulation A

Common stock, par value $0.0001

1-K: Summary Information Regarding Prior Offering and Proceeds

Summary Information

Checkbox not checkedThe following information must be provided for any Regulation A offering that has terminated or completed prior to the filing of this Form 1-K, unless such information has been previously reported in a manner permissible under Rule 257. If such information has been previously reported, check this box and leave the rest of Part I blank.

Commission File Number of the offering statement

024-10810

Date of qualification of the offering statement

03-29-2018

Date of commencement of the offering

03-03-2019

Amount of securities qualified to be sold in the offering

12850000

Amount of securities sold in the offering

10383364

Price per security

$ 6.0000

The portion of aggregate sales attributable to securities sold on behalf of the issuer

$ 59769350.00

The portion of the aggregate sales attributable to securities sold on behalf of selling securityholders

$ 0.00

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider Underwriters - Fees
$
Sales Commissions - Name of Service Provider
Dalmore Group, LLC
Sales Commissions - Fee
$ 597694.00
Finders' Fees - Name of Service Provider Finders' Fees - Fees
$
Accounting or Audit - Name of Service Provider
Deloitte & Touche LLP
Accounting or Audit - Fees
$ 168605.00
Legal - Name of Service Provider
Greenberg Traurig, P.A.
Legal - Fees
$ 386006.00
Promoters - Name of Service Provider Promoters - Fees
$
Blue Sky Compliance - Name of Service Provider
Various states
Blue Sky Compliance - Fees
$ 48470.00
CRD Number of any broker or dealer listed

136352

Net proceeds to the issuer

$ 55909523.00

Clarification of responses (if necessary)

Initially offered 10,000,000 shares at $5 per share. Price increase in July 2019, $6 per share. Additional 2,850,000 shares qualified in 2020. Fees include approximately $1.8 million for consultants/temp employees and $0.9 million other selling expenses.